Skip to main content
. 2017 Feb 19;2017:9531074. doi: 10.1155/2017/9531074

Figure 3.

Figure 3

Expression of miR-15a, miR-16-1, and miR-193a in sera from patients with NS. Relative expression levels of miR-15a (a) in patients with NS (nephrotic syndrome) and healthy subjects (HS) and (b) in patients with steroid-sensitive NS (SSNS) and steroid-resistant NS (SRNS). miR-16-1 (c) in patients with NS and HS and (d) in patients with SSNS and SRNS and miR-193a (e) in patients with NS and HS and (f) in patients with SSNS and SRNS.p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.